The Vancouver firm says its patch aims to skip needles and refrigeration, and it plans a further update once testing results are in. No outcome data yet.
Recap by typeshit. Full story at Yahoo Finance.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
A Houston Methodist Research Institute study found older adults with MASLD on GLP-1-based treatment had lower risk of hospitalization and death.
Covers the 28.3% versus 25.0% weight loss figures, the 12% who quit at 9 mg in TRIUMPH-2, and why online vials sold as Reta aren't the trial drug.
Loading…